ESSIG STUART
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
KeyBanc initiates IDEXX coverage with Sector Weight rating. KeyBanc has started covering IDEXX Laboratories, assigning it a Sector Weight rating. This move adds to analyst attention as investors look ahead to the company's upcoming Q3 2026 earnings report. The stock is currently trading near its 52-week high, reflecting strong recent performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.
Transaction History
| PIPR | ▲ Buy | Grant | 1,875 | $0 | 5/20/2026 | View on chart |
| PIPR | ▲ Buy | Grant | 175 | $0 | 2/4/2026 | View on chart |
| IART | ▼ Sell | Other | 200,000 | $2.7M | 8/14/2025 | View on chart |
| IART | ▼ Sell | Other | 200,000 | $2.7M | 8/14/2025 | View on chart |
| IART | ▲ Buy | Grant | 6,939 | $0 | 5/9/2025 | View on chart |
| IART | ▲ Buy | Grant | 24,898 | $0 | 5/9/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 262 | $0 | 5/6/2025 | View on chart |
| IART | ▲ Buy | Open Market | 52,641 | $1.5M | 5/23/2024 | View on chart |
| IART | ▲ Buy | Grant | 3,163 | $0 | 5/9/2024 | View on chart |
| IART | ▲ Buy | Grant | 10,672 | $0 | 5/9/2024 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 257 | $0 | 5/6/2024 | View on chart |
| IART | ▲ Buy | Grant | 5,505 | $0 | 5/12/2023 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 344 | $0 | 5/11/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 14,052 | $0 | 1/5/2023 | View on chart |
| IART | ▲ Buy | Grant | 4,215 | $0 | 5/13/2022 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 224 | $0 | 5/11/2022 | View on chart |
| IDXX | ▲ Buy | Grant | 49 | $24K | 1/28/2022 | View on chart |
| IDXX | ▲ Buy | Grant | 36 | $24K | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Piper Sandler faces valuation cut amid Perella Weinberg deal questions
Piper Sandler's fair value estimate was lowered as questions grew regarding the Perella Weinberg transaction. The firm also announced the creation of a new infrastructure debt advisory team in London and presented a forecast for Google's hardware revenue. These updates provide context for the stock's current position near its support level.
Piper Sandler faces valuation cut amid Perella Weinberg deal questions. Piper Sandler's fair value estimate was lowered as questions grew regarding the Perella Weinberg transaction. The firm also announced the creation of a new infrastructure debt advisory team in London and presented a forecast for Google's hardware revenue. These updates provide context for the stock's current position near its support level.